



Published in final edited form as:

*Curr Osteoporos Rep.* 2015 October ; 13(5): 318–326. doi:10.1007/s11914-015-0280-1.

## The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain

Rachel E. Miller, Ph.D.<sup>1,2</sup>, Phuong B. Tran, Ph.D.<sup>1</sup>, Alia Sondoqah, M.S.<sup>2</sup>, Padmanabhan Raghu, M.D.<sup>1</sup>, Shingo Ishihara, M.S.<sup>1</sup>, Richard J. Miller, Ph.D.<sup>3</sup>, and Anne-Marie Malfait, M.D., Ph.D.<sup>1,2,\*</sup>

<sup>1</sup>Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, 1611 W. Harrison St, Suite 510, Chicago, IL 60612

<sup>2</sup>Department of Biochemistry, Rush University Medical Center, 1611 W. Harrison St, Suite 510, Chicago, IL 60612

<sup>3</sup>Department of Pharmacology, Northwestern University, Lurie 8-125, 303 E. Superior St, Chicago, IL 60611

### Abstract

Knee osteoarthritis is characterized by progressive damage and remodeling of all tissues in the knee joint. Pain is the main symptom associated with knee osteoarthritis. Recent clinical and pre-clinical studies shed light on the mechanisms that drive the pain associated with joint destruction. In this narrative review, we describe current knowledge regarding the changes in the peripheral and central nervous system that occur during the progression of osteoarthritis and discuss how therapeutic interventions may provide pain relief.

### Keywords

Osteoarthritis; pain; sensitization; animal models; nerve growth factor; sodium channels

## 1. Osteoarthritis is a major cause of chronic pain

Osteoarthritis (OA) is a painful disease of the synovial joint, most commonly affecting knees, hips, hands, and facet joints of the spine. Knee OA affects 27 million people in the

\*Corresponding author Anne-Marie Malfait, MD, PhD, Associate Professor of Medicine, anne-marie\_malfait@rush.edu, T: 312-563-2925, F: 312-563-2267.

### Annotated Reference List

\*\*Usoskin et al

This study demonstrates the diversity of sensory neurons and reveals new distinct sub-types of nociceptors.

\*Ishikawa et al

A single dose of anti-NGF antibody early in the MIA model resulted in long-term improvement in gait imbalance despite no improvement in inflammation.

\*Rahman et al

Blocking the voltage-gated sodium channels Na<sub>v</sub>1.7 and Na<sub>v</sub>1.8 resulted in decreased dorsal horn neuronal responses to a variety of mechanical and thermal stimuli in the MIA model.

\*\*Stoppiello et al

This study shows that increased levels of synovitis and synovial levels of NGF are associated with symptomatic as compared to asymptomatic OA.

US (1), and the lifetime risk of developing symptomatic knee OA is estimated to be ~45% (2). Aging, prior joint injury, obesity, gender, and genetics are among the leading risk factors for OA. The major symptoms of knee OA include pain and related functional impairment (3, 4). In early stages of the disease, specific activities trigger sharp pain in a predictable fashion (5). As the disease progresses, the pain becomes chronic and is described as constant dull/aching pain in combination with unpredictable episodes of acute pain. Options for symptom management include both pharmacologic and non-pharmacologic treatments (6), but the effectiveness of these treatments remains limited (7). The inability to control pain is the major reason for total joint replacement (8), and OA is the principal diagnosis associated with total knee replacement (9).

OA represents failure of the synovial joint as an organ (10). The radiographic manifestations of OA (joint space narrowing, subchondral bone sclerosis and osteophytes) represent the late stage of a joint remodeling process that has often been going on for many years, and is characterized by progressive articular cartilage degradation, sclerosis of the subchondral bone, remodelling at the joint margins leading to osteophyte growth, low-grade synovitis, and meniscal damage in the knee (10). These remodeling processes result in profound changes in the biochemical milieu of the joint and in the joint mechanics, which may contribute to generation and maintenance of pain. Tissue remodeling probably also involves changes in joint innervation, which may also affect pain pathways. As in all forms of chronic pain, sensitization of the nervous system contributes to persistent OA pain, and there is abundant evidence that this sensitization is driven by the joint/periphery in most patients (11). In this narrative review, we describe what is known from both human and pre-clinical studies regarding changes in innervation and vascularization of the normal versus the OA joint and possible factors that may contribute to the development of peripheral and central sensitization, underlying persistent OA pain. We will focus specifically on knee OA, since both the clinical and the preclinical literature largely focus on this joint.

## 2. Animal models of OA pain

A variety of animal models are used for the study of OA and associated pain and each model has advantages and disadvantages (for review (12–14)). For the purposes of this review, we will focus on rodent models. Rats are often chosen for behavioral studies due to the fact that they are easier to train, while mice offer the opportunity to create transgenic models.

OA pain models may be divided into two main groups: chemically induced models and surgically induced models. The two most common pain-related behavioral changes reported include mechanical allodynia of the hind paw, defined as a painful sensation induced by a non-noxious stimulus, and deficits in weight-bearing on the affected limb. Other behavioral tests indicative of pain are in development, including gait analysis, knee hyperalgesia, conditioned placement preference, spontaneous locomotion activities, temperature hypersensitivity, and burrowing (13, 15).

The most commonly used model for the study of OA-associated pain in rodents is induced by intra-articular (IA) injection of monosodium iodoacetate (MIA), which results in chondrocyte death. This causes acute inflammation and aggressive development of joint

damage over the course of 3–4 weeks, often accompanied by mechanical allodynia and weight-bearing deficits (16, 17). It has been suggested that the early, transient synovial inflammation observed in MIA-treated rats may be the primary cause of initial pain in these animals (16), whereas later more persistent pain has been correlated with changes in joint histology (18).

Another chemically induced model that is gaining popularity is the collagenase-induced instability model (19). IA injection of collagenase results in damage to collagen type I containing structures such as tendons, ligaments, and menisci, resulting in joint instability (19). In the mouse, this induces medial and lateral cartilage destruction and subchondral bone sclerosis over a period of 6 weeks (19) and includes moderate levels of synovitis (20), perhaps providing a model for a more inflammatory subset of OA. Joint damage is associated with weight-bearing deficits in mice (21) and with mechanical allodynia and thermal hyperalgesia in rats (22).

Surgical models of OA include the rat medial meniscal tear (MMT) model, where transection of the medial collateral ligament followed by cutting of the medial meniscus at its narrowest point leads to progressive degenerative cartilage changes over 3–6 weeks (23). Joint damage is accompanied by mechanical allodynia and weight-bearing deficits (24). According to one side-by-side comparison, the rat MMT model displays more inflammation, osteophyte formation and weight-bearing asymmetry than the MIA model (25).

Destabilization of the medial meniscus (DMM) is currently the most commonly used mouse model of OA, and is performed by severing the medial meniscotibial ligament, causing mild instability of the knee (26). The slowly progressive nature of this model (typically monitored up to 8 to 16 weeks after surgery) makes it well-suited for studying OA pathophysiology and molecular mechanisms (27–29). In addition to cartilage damage primarily on the medial side of the joint, pathological features include subchondral bone thickening, osteophytes, and low-grade synovitis (30). As in the previous models, both mechanical allodynia (28, 29) and weight-bearing deficits have been reported (27). Mechanical allodynia develops over the first four weeks after DMM but not sham surgery and is maintained through 16 weeks (28, 29), while weight-bearing deficits first develop by 10–12 weeks after surgery (27). Locomotion deficits (decreased distance traveled, rearing, and climbing upside down) have also been detected in this model beginning 8 weeks after surgery (27, 29).

The partial meniscectomy mouse model is induced by freeing the medial meniscus from the attachment to the margin of the tibial plateau and removing approximately half of the medial meniscus (approximately 1 mm of tissue) (31). The collateral ligament is left intact. In contrast to the DMM model, female mice may be used. This surgery results in progressive cartilage destruction over a period of 12 weeks; synovitis has not been assessed. Mice developed persistent paw pressure hypersensitivity, cold hypersensitivity and knee pressure hypersensitivity by week 5 after surgery and significant mechanical allodynia by week 8 (31). Statistically significant weight-bearing deficits were not detected, but a significant amount of variation was present in both the sham and partial meniscectomy groups perhaps reflecting the difficulty in measuring this behavior in mice.

### 3. Peripheral sensitization

#### 3.1 Overview of Neuroanatomy

The knee joint is innervated by both sensory and sympathetic peripheral nerve fibers (32, 33). The cell bodies of the sensory neurons that innervate the knee joint are located in the dorsal root ganglia (DRG), primarily levels L3 to L5. These pseudo-unipolar neurons extend branches to the peripheral structures such as the knee joint and also extend branches centrally to the dorsal horn of the spinal cord, where the first synapse is made with interneurons or with supraspinally-projecting neurons, carrying pain signals to the higher regions of the neuraxis where they are ultimately experienced by the conscious brain.

The pain-sensing sensory neurons, or nociceptors, are small-diameter unmyelinated C-fibers (slow-conduction) or medium-diameter thinly myelinated A $\delta$ -fibers (fast-conduction). Nociceptors have been sub-divided based on their ability to respond to particular types of stimuli (34). Traditionally, C-fiber nociceptors were separated into two sub-types, peptidergic or non-peptidergic, based on their ability to produce the neuropeptides substance P and calcitonin gene-related peptide (CGRP). In addition, peptidergic neurons were attributed with expression of TrkA, a receptor for nerve growth factor (NGF). Non-peptidergic neurons were identified by their ability to bind isolectin IB4, to express the c-Ret neurotrophin receptor that is targeted by glial-derived neurotrophic factor (GDNF), and to express purinergic receptors that respond to ATP. It has since been discovered that in fact multiple distinct types of nociceptors can be defined, with one sub-type expressing both peptidergic and non-peptidergic markers (34). Ongoing work is focused on determining which subsets of neurons mediate mechanisms underlying touch, itch, and pain, and little is known regarding which subsets of neurons are important for driving pain associated with disease, including OA.

#### 3.2 Tissue Damage Mediators of Pain

Acute or 'protective' pain is stimulated through direct transduction of strong chemical, thermal, or mechanical stimuli into action potentials in order to generate a very fast response with the goal of protecting the peripheral tissue from injury (35). Tissue injury, including the tissue remodeling characteristic of OA (36), produces a different biochemical milieu in joints than the set of molecules that facilitates normal acute pain responses. In OA, these injury products may include classical inflammatory molecules such as prostaglandins and bradykinins, as well as cytokines and chemokines. All of these molecules have been shown to excite pain-sensing sensory neurons (nociceptors) (for review (35, 37, 38)). In addition, recent evidence suggests that damage-associated molecular products (DAMPs), associated with inflammation in OA (39), also may directly excite sensory neurons (40–44). As a result of continued stimulation by these tissue injury products, peripheral nociceptors may become sensitized, meaning that the threshold for activation is reduced.

Animal models of OA enable molecular and cellular characterization of peripheral sensitization associated with changes in pain-related behaviors. Recent reviews have focused on the role of cytokines, neuropeptides, and cannabinoids in the development of peripheral

sensitization in OA (38, 45, 46). Therefore, here we will focus on describing the potential role of NGF, sodium channels, and non-neuronal cells to peripheral sensitization in OA.

NGF signaling has emerged as an analgesic target for a variety of diseases (47), including OA (48), and preliminary clinical trial results are encouraging despite some issues with adverse effects in a subset of patients. Peripheral inflammation has been shown to increase NGF expression in the inflamed tissue (47), and gene expression levels of NGF and its high-affinity receptor, TrkA, are upregulated by human OA chondrocytes (49). Retrograde transport of NGF to the DRG can cause altered gene expression, which can result in increased neuropeptide (substance P and CGRP) and ion channel production and can even cause non-peptidergic neurons to switch to a peptidergic phenotype (47). In rat MIA and rat MMT, the TrkA receptor was upregulated in both ipsilateral and contralateral DRG neurons by the time that persistent pain behaviors present (50). In murine DMM, increased NGF mRNA levels were found in the knee joints in the persistent phase stage (16 weeks after surgery), and systemic administration of TrkAd5, a human soluble NGF receptor, resulted in reversal of weight-bearing deficits at this time point (51). IA injection of NGF into the knee joint of rats following induction of OA by either MMT surgery or MIA injection resulted in increased and sustained weight-bearing deficits compared to NGF effects in control knees (50). Secondary mechanical allodynia of the hind paw was not further reduced following IA NGF injection in OA rats (50). Supporting these findings, IA injection of NGF increased firing of spinal neurons in response to knee extension but not in response to noxious stimulation of the hind paw in MIA-injected rats (52). Together, these studies suggest that NGF may play a role in peripheral sensitization in OA.

Previous studies in non-OA models have demonstrated that mechanical hyperalgesia stimulated by NGF appears to be a result of direct action on peripheral nerves as opposed to regulation of local cytokine production and other inflammatory processes that may be involved in joint destruction (53–55). Similar results have been noted in the rat MIA model. Prophylactic treatment of rats with indomethacin prior to MIA injection was able to prevent TrkA upregulation in the DRG and reduce sensitivity to IA injection of NGF, but it had no effect on synovitis or joint swelling (50). In another study, a single systemic dose of an anti-NGF antibody 3 days after MIA injection resulted in decreased gait deficits by day 35, despite the fact that treatment did not affect joint swelling and development of macroscopic cartilage lesions (56). The relative contributions of the two different NGF receptors, TrkA and p75, have not been fully elucidated in the context of OA pain.

Voltage-gated sodium channels expressed on nociceptors serve to generate and propagate action potentials in response to painful stimuli, and altered expression and sensitivity of these channels has been linked to chronic pain (57). A recent study has begun to address the role of sodium channels in OA, by targeting voltage-gated sodium channels ( $\text{Na}_v$ ) 1.7 and 1.8 in the MIA rat model (58). Both  $\text{Na}_v$ 1.7 and  $\text{Na}_v$ 1.8 are expressed by nociceptors and have been identified on both the peripheral and central terminals of these neurons. Two weeks after induction of MIA, spinal administration of ProTxII, a tarantula toxin that blocks  $\text{Na}_v$ 1.7, or A-803467, an inhibitor of  $\text{Na}_v$ 1.8, resulted in decreased responses of wide dynamic range spinal dorsal horn neurons in response to mechanical and thermal stimuli applied to the hind paw (58). There was no effect on sham rats. In addition, systemic (s.c.)

or intraplantar administration of A-803467 resulted in a decreased response by spinal neurons. This supports a previous study demonstrating the ability of an IA injection of A-803467 to inhibit the firing of knee joint afferents in response to noxious rotation of the joint and to inhibit mechanical allodynia and weight-bearing deficits in rats 14 days after induction of OA via MIA injection (59). Together, these studies suggest that targeting peripheral sodium channels may be an effective treatment option in treating persistent OA pain.

Finally, another aspect of peripheral sensitization may include the infiltration and activation of inflammatory cells within the DRG itself. This process may help to promote the persistence of pain (60). In the DMM model, macrophage (F4/80-positive cells) infiltration into the DRG correlated with the development of persistent pain behaviors (29). In addition, in the antigen-induced arthritis model, macrophage infiltration into the DRG was significant 3 days after induction and these cells expressed markers consistent with macrophages activated by TNF- $\alpha$ , a sub-type of M1-macrophages that can produce factors supporting neuronal activation but that do not promote cell death (61). Further work is needed to understand whether reversing these inflammatory processes in the DRG results in pain relief.

### 3.3 Innervation and vascularization changes in the osteoarthritic knee

As outlined above, the majority of inflammatory mediators found in OA joints have the ability to stimulate knee-innervating nociceptors and many types of nociceptors may be present in the joint. Therefore, a better understanding of the innervation of the normal joint, and the changes that occur during the course of OA may lead to new analgesic targets.

A pioneering study performed by two orthopaedic surgeon brothers determined which intra-articular tissues elicited pain within a normal knee (62). One brother arthroscopically palpated the intra-articular knee tissues of the other brother without intra-articular anesthesia. Entry into the intra-articular space through the anterior synovium and fat pad resulted in severe pain. Palpation of the suprapatellar pouch, capsule, and the medial and lateral retinacula (connective tissue surrounding the patella) with low forces resulted in moderate to severe pain. Higher forces were required to elicit moderate to severe pain from the tibial and femoral insertion sites of the cruciate ligaments. Likewise, medium-to-high force resulted in slight to moderate discomfort upon probing of the anterior and posterior horns of the meniscus. These observations are in line with the innervation of the normal knee, in which sensory nerves have been identified in the synovium, ligament and tendon insertion sites, outer meniscus, and subchondral bone (63), while normal cartilage is aneural and avascular.

Few studies have compared the sensory innervation in human OA and age-matched healthy joints. Vascular changes have been described in more detail, including in human OA and age-matched healthy joints, and may contribute to OA pathogenesis (63). Since new blood vessel growth and nerve growth share common mechanisms, it has been posited that nerve growth may accompany angiogenesis in OA (for review (63)).

Neovascularization of the non-calcified cartilage just above the osteochondral junction is associated with perivascular sensory (substance P- and calcitonin gene-related peptide (CGRP)-positive) and sympathetic (C-flanking peptide of neuropeptide Y (CPON)-positive) innervation (64). Vascularization of the osteochondral region has been correlated with cartilage damage (65) and with subchondral bone marrow replacement by fibrovascular tissue (66) in OA. This process is associated with up-regulated expression of angiogenic factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) in the subchondral tissues and highly algogenic nerve growth factor (NGF) expression within vascular channels (66). Sensory and sympathetic innervation was also observed within the marrow cavities of tibial osteophytes (64).

One study examined vascular penetration and nerve growth in human menisci, comparing menisci from postmortem knees with a high versus a low degree of macroscopic tibiofemoral cartilage damage (67). Knees with high degree of chondropathy showed greater vascular density near the fibrocartilage junction (defined as the region dividing the outer third from the inner meniscus) (67). CGRP-positive sensory nerve fibers were often present alongside blood vessels and increased numbers of nerves were identified in the outer region of menisci from the severe cartilage damage group compared to the mild cartilage damage group (67). This study did not include pain measures, but the results are consistent with MRI studies demonstrating increased meniscal pathologies in symptomatic versus asymptomatic subjects (68, 69).

Changes in the innervation of the anterior and posterior cruciate ligaments in OA have not been described in depth to date and conflicting results have been reported. One study compared posterior cruciate ligaments taken from 22 total knee arthroplasty patients and 3 normal post-mortem patients of a similar age and found no significant differences regarding the distribution of sensory nerve fibers (staining for neurofilament protein, S-100 protein, epithelial membrane antigen, and vimentin) (70). Another study comparing posterior cruciate ligaments from 9 total knee arthroplasty patients to 5 normal post-mortem or amputation patients of similar age observed a significant reduction in the percentage area occupied by sensory nerves (gold chloride staining of free nerve endings) in the ligaments from osteoarthritic patients (71).

No published studies comparing the innervation of the synovium between OA and normal human subjects were identified. One study examined synovial tissues taken from 13 knee joints during total knee replacement surgery (symptomatic with K/L stage 3 or 4) with a range of synovitis scores (72). Looking at the correlation between nerve density (protein gene product (PGP) 9.5-positive, pan-neuronal marker) and synovitis score, it was found that increasing synovitis resulted in decreased nerve density close to the synovial lining, but in deeper layers, the nerve fiber density remained constant with increasing synovitis score (72). Another study examined changes in vascularity in synovium and found that endothelial cell proliferation, particularly at locations distant from the synovial lining, increased with increasing synovitis in OA but was not related to levels of osteochondral angiogenesis or to cartilage damage severity (65). Finally, one study examined nerve growth factor (NGF) expression in the synovium. NGF-positive fibroblasts and macrophages were observed in areas of the synovial lining and sublining where blood vessels were also present, and the

fractional areas positive for these cells was elevated in the synovium of advanced OA patients compared to non-OA controls (73). This study also demonstrated that advanced symptomatic OA is associated with synovitis, synovial NGF immunoreactivity, changes in chondrocyte morphology, and loss of cartilage surface integrity as compared with the advanced asymptomatic OA group (73). Together, these studies suggest that increasing synovitis levels in end-stage OA may contribute to pain through vascular and nerve growth in the deeper synovial layers and through the production of proalgesic products, particularly NGF, by synovial fibroblasts and macrophages.

In animal models of OA, two studies have examined innervation changes in the knee, using the collagenase-induced instability mouse model. Buma et al originally reported that, 5 weeks after injection, there were deficits in substance P- and CGRP-positive innervating fibers, at specific locations around the cruciate ligaments and in the synovium and other soft tissues around the patella (74). Recently, Murakami et al. performed a study examining changes in innervation of the synovium 1–4 weeks after collagenase injection (75). Synovitis peaked 1–2 weeks after injection and remained elevated compared to contralateral knees 3–4 weeks after injection. Interestingly, PGP 9.5-positive nerve fiber density was decreased 1–2 weeks after injection but returned to normal levels by 3–4 weeks. Likewise, CGRP-positive nerve fiber density was decreased one week after injection, whereas no change was observed in the density of substance P-positive nerve fibers. Three studies reported that non-peptidergic nerve fibers (IB4-positive) are present at very low levels in the rat knee joint (1.5% or less of all cells retrogradely labeled by IA injection), but all of these studies looked at colocalization of IB4 with retrograde label in the dorsal root ganglion cell bodies instead of in the joint structures themselves (76–78). In addition, one study reports the presence of tyrosine hydroxylase (TH)-positive neurons in the deep layers of the normal rat synovium, but it is not clear from this study whether this represents the sympathetic neuron population (79) or the sensory neuron population known to express TH (80). Overall, there is a need for further characterization of the different nociceptor subtypes in the knee and how the location and types of nerves changes in OA.

#### 4. Central Sensitization

OA pain may be driven by abnormal excitability in the pain pathways of both the peripheral and central nervous systems. Intense, repeated, or prolonged input from peripheral nociceptors can also lead to central sensitization (81), defined as an amplification of neuronal signaling within the central nervous system (CNS) that elicits pain hypersensitivity (82). Therefore, this represents a state where normally innocuous stimuli may now be interpreted as painful.

The causes leading to central sensitization are multifaceted. Following peripheral sensitization, it is known that primary afferent-mediated transmission to neurons in the dorsal horn of the spinal cord becomes strengthened by a variety of mechanisms (83). For example, sustained sensory input from nociceptors originating in the periphery interrupts descending inhibition of spinal dorsal horn neurons, which results in a reduction in their excitation threshold and allows for potentiation of pain signals (84).



Characterizing changes in clinical measures of sensitization in OA is a burgeoning area of research. In particular, determining whether central sensitization may play a role in chronic OA pain is important for informing therapeutic strategies. Clinical measures of sensitization include pressure pain threshold (PPT) testing, sensitivity mapping, mechanical temporal summation, mechanical allodynia, and conditioned pain modulation (4, 82). A recently published systematic review of pressure pain threshold (PPT) and heat pain threshold (HPT) studies suggests that sensitization in knee OA patients may be associated with symptom severity (85). Another recent systematic review suggests that OA pain is associated with central sensitization in a subset of patients, particularly those people with chronic pain (86). Two studies have demonstrated that following successful total knee arthroplasty, measures of sensitization are normalized (87, 88), indicating that continuous peripheral input is important for maintenance of sensitization in OA. Additional high quality studies are necessary to better understand which subset(s) of patients, possibly in a particular stage of disease, may benefit from centrally acting therapeutics.

In general, the relationship between peripheral sensitization and central sensitization must be further explored in OA in order to determine whether or not reducing peripheral sensitization is a *sine qua non* for central sensitization.

Changes at the level of the spinal cord have only been investigated in the MIA model thus far; no surgical models have been studied. During the late phase of the MIA model (28 days post injection), when both mechanical allodynia and weight-bearing deficits are established, spinal neurons of MIA rats displayed increased excitability in response to mechanical stimulation of the hind paw compared to saline-treated rats (18). In addition, studies have shown that in the spinal cord there is a time dependent activation of microglia (7–14 days post-MIA) followed by astrocyte activation (28 days post-MIA) (18, 89–91). However, in the mouse MIA model, microgliosis was seen only at the later time point and astrocytosis was not observed (92). Together, these spinal changes suggest that central sensitization contributes to the aberrant pain responses in the late pain stage of this model.

Analgesic testing in the MIA model further supports a central component for pain behaviors during the late stage of the model. Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to reverse pain behaviors up to 14 days after a 1 mg MIA injection (16, 93, 94). Gabapentin, which has both peripheral and central sites of action, is able to reverse behaviors during the late phase of the model (days 14–28) (93, 95). Amitriptyline, which most likely acts on the spinal cord, is also effective in reversing behaviors during the late phase of the model (days 14–28) (93). Finally, systemic treatment with minocycline or nimesulide was associated with a reduction in microglia and astrocyte activation in the dorsal horn and with an attenuation of mechanical allodynia in the late phase of the model (90).

## 5. Conclusions and Future Directions

Clinical and pre-clinical studies support the hypothesis that the tissue damage characteristic of osteoarthritis contributes to the development and maintenance of osteoarthritis pain. Future work should be directed at better understanding exactly how joint damage results in

sensitization of the peripheral and central nervous system. For example, within the joint itself, little is known regarding the receptors expressed by peripheral nerve termini under normal and pathological conditions. Additionally, few studies have directly compared the innervation of the normal joint to the OA joint using samples from age-matched samples in which symptoms and sensitization have been characterized in order to understand how this pathophysiological feature may be related to pain. Finally, both peripheral and central sensitization contribute to OA pain, but continued effort should be focused on understanding under what circumstances this sensitization can be reversed.

## Acknowledgements

Rachel Miller was supported by the US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (F32AR062927). Anne-Marie Malfait (R01AR064251 and R01AR060364) and Richard Miller (R01AR064251) were supported by NIAMS.

## References

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum.* 2008; 58(1):26–35. [PubMed: 18163497]
2. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, et al. Lifetime risk of symptomatic knee osteoarthritis. *Arthritis Rheum.* 2008; 59(9):1207–1213. [PubMed: 18759314]
3. Creamer P, Lethbridge-Cejku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. *Rheumatology (Oxford).* 2000; 39(5):490–496. [PubMed: 10852978]
4. Neogi T. The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis Cartilage.* 2013; 21(9):1145–1153. [PubMed: 23973124]
5. Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, et al. Understanding the pain experience in hip and knee osteoarthritis--an OARSI/OMERACT initiative. *Osteoarthritis Cartilage.* 2008; 16(4):415–422. [PubMed: 18296075]
6. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken).* 2012; 64(4):465–474. [PubMed: 22563589]
7. Hunter DJ, Neogi T, Hochberg MC. Quality of osteoarthritis management and the need for reform in the US. *Arthritis Care Res (Hoboken).* 2011; 63(1):31–38. [PubMed: 20583113]
8. Riddle DL, Perera RA, Stratford PW, Jiranek WA, Dumenci L. Progressing toward, and recovering from, knee replacement surgery: a five-year cohort study. *Arthritis Rheum.* 2013; 65(12):3304–3313. [PubMed: 23983118]
9. United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS) [Internet]. 2014 Available from: <http://www.boneandjointburden.org>.
10. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum.* 2012; 64(6):1697–1707. [PubMed: 22392533]
11. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. *Nat Rev Rheumatol.* 2013; 9(11):654–664. [PubMed: 24045707]
12. Little CB, Zaki S. What constitutes an "animal model of osteoarthritis"--the need for consensus? *Osteoarthritis Cartilage.* 2012; 20(4):261–267. [PubMed: 22321719]
13. Malfait AM, Little CB, McDougall JJ. A commentary on modelling osteoarthritis pain in small animals. *Osteoarthritis Cartilage.* 2013; 21(9):1316–1326. [PubMed: 23973146]
14. Malfait AM, Little CB. On the Predictive Utility of Animal Models of Osteoarthritis. *Arthritis research & therapy.* In press.

15. Bryden LA, Nicholson JR, Doods H, Pekcec A. Deficits in spontaneous burrowing behavior in the rat bilateral monosodium iodoacetate model of osteoarthritis: an objective measure of pain-related behavior and analgesic efficacy. *Osteoarthritis Cartilage*. In press.
16. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. *Osteoarthritis Cartilage*. 2003; 11(11):821–830. [PubMed: 14609535]
17. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? *Neurosci Lett*. 2004; 370(2–3):236–240. [PubMed: 15488329]
18. Sagar DR, Stanciaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, et al. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. *Arthritis Rheum*. 2010; 62(12):3666–3676. [PubMed: 20722027]
19. van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB. Degenerative knee joint lesions in mice after a single intra-articular collagenase injection. A new model of osteoarthritis. *J Exp Pathol (Oxford)*. 1990; 71(1):19–31. [PubMed: 2155638]
20. van Lent PL, Blom AB, Schelbergen RF, Sloetjes A, Lafeber FP, Lems WF, et al. Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. *Arthritis Rheum*. 2012; 64(5):1466–1476. [PubMed: 22143922]
21. Cook AD, Pobjoy J, Steidl S, Durr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. *Arthritis Res Ther*. 2012; 14(5):R199. [PubMed: 22995428]
22. Lee CH, Wen ZH, Chang YC, Huang SY, Tang CC, Chen WF, et al. Intra-articular magnesium sulfate (MgSO<sub>4</sub>) reduces experimental osteoarthritis and nociception: association with attenuation of N-methyl-D-aspartate (NMDA) receptor subunit 1 phosphorylation and apoptosis in rat chondrocytes. *Osteoarthritis Cartilage*. 2009; 17(11):1485–1493. [PubMed: 19490963]
23. Bendele AM. Animal models of osteoarthritis. *J Musculoskelet Neuronal Interact*. 2001; 1(4):363–376. [PubMed: 15758487]
24. Bove SE, Laemont KD, Brooker RM, Osborn MN, Sanchez BM, Guzman RE, et al. Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia. *Osteoarthritis Cartilage*. 2006; 14(10):1041–1048. [PubMed: 16769229]
25. Mapp PI, Sagar DR, Ashraf S, Burston JJ, Suri S, Chapman V, et al. Differences in structural and pain phenotypes in the sodium monoiodoacetate and meniscal transection models of osteoarthritis. *Osteoarthritis Cartilage*. 2013; 21(9):1336–1345. [PubMed: 23973148]
26. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis Cartilage*. 2007; 15(9):1061–1069. [PubMed: 17470400]
27. Inglis JJ, McNamee KE, Chia SL, Essex D, Feldmann M, Williams RO, et al. Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. *Arthritis Rheum*. 2008; 58(10):3110–3119. [PubMed: 18821665]
28. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, et al. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. *Osteoarthritis Cartilage*. 2010; 18(4):572–580. [PubMed: 20036347]
29. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. *Proc Natl Acad Sci U S A*. 2012; 109(50):20602–20607. [PubMed: 23185004]
30. Jackson MT, Moradi B, Zaki S, Smith MM, McCracken S, Smith SM, et al. Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms. *Arthritis Rheumatol*. 2014; 66(12):3337–3348. [PubMed: 25200274]
31. Knights CB, Gentry C, Bevan S. Partial medial meniscectomy produces osteoarthritis pain-related behaviour in female C57BL/6 mice. *Pain*. 2012; 153(2):281–292. [PubMed: 22001658]
32. Samuel EP. The autonomic and somatic innervation of the articular capsule. *Anat Rec*. 1952; 113(1):53–70. [PubMed: 14924262]

33. Skoglund S. Anatomical and physiological studies of knee joint innervation in the cat. *Acta Physiol Scand Suppl.* 1956; 36(124):1–101. [PubMed: 13326493]
34. Usoskin D, Furlan A, Islam S, Abdo H, Lonnerberg P, Lou D, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. *Nat Neurosci.* 2015; 18(1):145–153. [PubMed: 25420068]
35. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nat Rev Neurosci.* 2005; 6(7):521–532. [PubMed: 15995723]
36. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. *Ther Adv Musculoskelet Dis.* 2013; 5(2):77–94. [PubMed: 23641259]
37. Miller RJ, Jung H, Bhangoo SK, White FA. Cytokine and chemokine regulation of sensory neuron function. *Handb Exp Pharmacol.* 2009(194):417–449. [PubMed: 19655114]
38. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. *Cytokine.* 2014; 70(2):185–193. [PubMed: 25066335]
39. Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. *Nat Rev Rheumatol.* 2015; 11(1):35–44. [PubMed: 25266449]
40. Allette YM, Due MR, Wilson SM, Feldman P, Ripsch MS, Khanna R, et al. Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain. *Brain Behav Immun.* 2014
41. Liu T, Xu ZZ, Park CK, Berta T, Ji RR. Toll-like receptor 7 mediates pruritus. *Nature neuroscience.* 2010; 13(12):1460–1462. [PubMed: 21037581]
42. Qi J, Buzas K, Fan H, Cohen JI, Wang K, Mont E, et al. Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. *J Immunol.* 2011; 186(11):6417–6426. [PubMed: 21515789]
43. Shibasaki M, Sasaki M, Miura M, Mizukoshi K, Ueno H, Hashimoto S, et al. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. *Pain.* 2010; 149(3):514–521. [PubMed: 20392563]
44. Miller RE, Belmadani A, Ishihara S, Tran PB, Ren D, Miller RJ, et al. Damage-Associated Molecular Patterns Generated in Osteoarthritis Directly Excite Murine Nociceptive Neurons through Toll-like Receptor 4. *Arthritis Rheumatol.* 2015
45. Walsh DA, Mapp PI, Kelly S. Calcitonin gene-related peptide in the joint: contributions to pain and inflammation. *Br J Clin Pharmacol.* 2015
46. Zhang RX, Ren K, Dubner R. Osteoarthritis pain mechanisms: basic studies in animal models. *Osteoarthritis Cartilage.* 2013; 21(9):1308–1315. [PubMed: 23973145]
47. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. *Anesthesiology.* 2011; 115(1):189–204. [PubMed: 21602663]
48. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. *N Engl J Med.* 2010; 363(16):1521–1531. [PubMed: 20942668]
49. Iannone F, De Bari C, Dell'Accio F, Covelli M, Patella V, Lo Bianco G, et al. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. *Rheumatology (Oxford).* 2002; 41(12):1413–1418. [PubMed: 12468822]
50. Ashraf S, Mapp PI, Burston J, Bennett AJ, Chapman V, Walsh DA. Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis. *Ann Rheum Dis.* 2014; 73(9):1710–1718. [PubMed: 23852764]
51. McNamee KE, Burleigh A, Gompels LL, Feldmann M, Allen SJ, Williams RO, et al. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. *Pain.* 2010; 149(2):386–392. [PubMed: 20350782]
52. Sagar DR, Nwosu L, Walsh DA, Chapman V. Dissecting the contribution of knee joint NGF to spinal nociceptive sensitization in a model of OA pain in the rat. *Osteoarthritis Cartilage.* 2015; 23(6):906–913. [PubMed: 25623624]
53. Malik-Hall M, Dina OA, Levine JD. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. *Eur J Neurosci.* 2005; 21(12):3387–3394. [PubMed: 16026476]

54. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. *Pain*. 2005; 116(1–2):8–16. [PubMed: 15927377]
55. Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, Li X, et al. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. *Pain*. 2008; 138(1):47–60. [PubMed: 18083307]
56. Ishikawa G, Koya Y, Tanaka H, Nagakura Y. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis. *Osteoarthritis Cartilage*. 2015; 23(6):925–932. [PubMed: 25677108]
57. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. *Annu Rev Neurosci*. 2010; 33:325–347. [PubMed: 20367448]
58. Rahman W, Dickenson AH. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat. *Neuroscience*. 2015; 295:103–116. [PubMed: 25818052]
59. Schuelert N, McDougall JJ. Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritis. *Arthritis Res Ther*. 2012; 14(1):R5. [PubMed: 22225591]
60. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nat Med*. 2010; 16(11):1267–1276. [PubMed: 20948535]
61. Massier J, Eitner A, von Banchet GS, Schaible HG. Effects of differently activated rodent macrophages on sensory neurons. Implications for arthritic pain. *Arthritis Rheumatol*. 2015
62. Dye SF, Vaupel GL, Dye CC. Conscious neurosensory mapping of the internal structures of the human knee without intraarticular anesthesia. *Am J Sports Med*. 1998; 26(6):773–777. [PubMed: 9850777]
63. Mapp PI, Walsh DA. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. *Nat Rev Rheumatol*. 2012; 8(7):390–398. [PubMed: 22641138]
64. Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF, Walsh DA. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. *Ann Rheum Dis*. 2007; 66(11):1423–1428. [PubMed: 17446239]
65. Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, McWilliams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. *Osteoarthritis Cartilage*. 2007; 15(7):743–751. [PubMed: 17376709]
66. Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE, Mapp PI, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. *Rheumatology (Oxford)*. 2010; 49(10):1852–1861. [PubMed: 20581375]
67. Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. *Ann Rheum Dis*. 2011; 70(3):523–529. [PubMed: 21081524]
68. Fukuta S, Kuge A, Korai F. Clinical significance of meniscal abnormalities on magnetic resonance imaging in an older population. *Knee*. 2009; 16(3):187–190. [PubMed: 19179080]
69. Fukuta S, Masaki K, Korai F. Prevalence of abnormal findings in magnetic resonance images of asymptomatic knees. *J Orthop Sci*. 2002; 7(3):287–291. [PubMed: 12077651]
70. Del Valle ME, Harwin SF, Maestro A, Murcia A, Vega JA. Immunohistochemical analysis of mechanoreceptors in the human posterior cruciate ligament: a demonstration of its proprioceptive role and clinical relevance. *J Arthroplasty*. 1998; 13(8):916–922. [PubMed: 9880185]
71. Franchi A, Zaccherotti G, Aglietti P. Neural system of the human posterior cruciate ligament in osteoarthritis. *J Arthroplasty*. 1995; 10(5):679–682. [PubMed: 9273382]
72. Eitner A, Pester J, Nietzsche S, Hofmann GO, Schaible HG. The innervation of synovium of human osteoarthritic joints in comparison with normal rat and sheep synovium. *Osteoarthritis Cartilage*. 2013; 21(9):1383–1391. [PubMed: 23973153]
73. Stoppigliello LA, Mapp PI, Wilson D, Hill R, Scammell BE, Walsh DA. Structural associations of symptomatic knee osteoarthritis. *Arthritis Rheumatol*. 2014; 66(11):3018–3027. [PubMed: 25049144]

74. Buma P, Verschuren C, Versleyen D, Van der Kraan P, Oestreicher AB. Calcitonin gene-related peptide, substance P and GAP-43/B-50 immunoreactivity in the normal and arthrotic knee joint of the mouse. *Histochemistry*. 1992; 98(5):327–339. [PubMed: 1283163]
75. Murakami K, Nakagawa H, Nishimura K, Matsuo S. Changes in peptidergic fiber density in the synovium of mice with collagenase-induced acute arthritis. *Can J Physiol Pharmacol*. 2015:1–7.
76. Fernihough J, Gentry C, Bevan S, Winter J. Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. *Neurosci Lett*. 2005; 388(2):75–80. [PubMed: 16039054]
77. Ferreira-Gomes J, Adaes S, Sarkander J, Castro-Lopes JM. Phenotypic alterations of neurons that innervate osteoarthritic joints in rats. *Arthritis Rheum*. 2010; 62(12):3677–3685. [PubMed: 20722015]
78. Ivanavicius SP, Blake DR, Chessell IP, Mapp PI. Isolectin B4 binding neurons are not present in the rat knee joint. *Neuroscience*. 2004; 128(3):555–560. [PubMed: 15381284]
79. Burgi K, Cavalleri MT, Alves AS, Britto LR, Antunes VR, Michelini LC. Tyrosine hydroxylase immunoreactivity as indicator of sympathetic activity: simultaneous evaluation in different tissues of hypertensive rats. *Am J Physiol Regul Integr Comp Physiol*. 2011; 300(2):R264–R271. [PubMed: 21148479]
80. Li L, Rutlin M, Abraira VE, Cassidy C, Kus L, Gong S, et al. The functional organization of cutaneous low-threshold mechanosensory neurons. *Cell*. 2011; 147(7):1615–1627. [PubMed: 22196735]
81. Mease PJ, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. *J Rheumatol*. 2011; 38(8):1546–1551. [PubMed: 21632678]
82. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*. 2011; 152(3 Suppl):S2–S15. [PubMed: 20961685]
83. Lee Y, Pai M, Brederson JD, Wilcox D, Hsieh G, Jarvis MF, et al. Monosodium iodoacetate-induced joint pain is associated with increased phosphorylation of mitogen activated protein kinases in the rat spinal cord. *Mol Pain*. 2011; 7:39. [PubMed: 21599960]
84. Murphy SL, Phillips K, Williams DA, Clauw DJ. The role of the central nervous system in osteoarthritis pain and implications for rehabilitation. *Curr Rheumatol Rep*. 2012; 14(6):576–582. [PubMed: 22879060]
85. Fingleton C, Smart K, Moloney N, Fullen BM, Doody C. Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis Cartilage*. 2015
86. Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. *Eur J Pain*. 2014; 18(10):1367–1375. [PubMed: 24700605]
87. Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. *Arthritis Rheum*. 2012; 64(9):2907–2916. [PubMed: 22421811]
88. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. *Pain*. 2000; 88(1):69–78. [PubMed: 11098101]
89. Orita S, Ishikawa T, Miyagi M, Ochiai N, Inoue G, Eguchi Y, et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. *BMC Musculoskelet Disord*. 2011; 12:134. [PubMed: 21679434]
90. Sagar DR, Burston JJ, Hathway GJ, Woodhams SG, Pearson RG, Bennett AJ, et al. The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain. *Mol Pain*. 2011; 7:88. [PubMed: 22093915]
91. Thakur M, Rahman W, Hobbs C, Dickenson AH, Bennett DL. Characterisation of a peripheral neuropathic component of the rat monoiodoacetate model of osteoarthritis. *PLoS One*. 2012; 7(3):e33730. [PubMed: 22470467]

92. Ogonna AC, Clark AK, Gentry C, Hobbs C, Malcangio M. Pain-like behaviour and spinal changes in the monosodium iodoacetate model of osteoarthritis in C57Bl/6 mice. *Eur J Pain*. 2013; 17(4):514–526. [PubMed: 23169679]
93. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. *Pain*. 2007; 128(3):272–282. [PubMed: 17276007]
94. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. *Pain*. 2005; 114(3):339–346. [PubMed: 15777859]
95. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, et al. Pain related behaviour in two models of osteoarthritis in the rat knee. *Pain*. 2004; 112(1–2):83–93. [PubMed: 15494188]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript